Back to search results

BEACON Trial: Comparing Flotufolastat F 18 Imaging to MRI for Prostate Cancer

This study, called the BEACON Trial, is looking at a new way to find prostate cancer using a special imaging agent called flotufolastat F 18. This agent helps doctors see prostate tumor cells on a PET/CT scan. The goal is to see if this new imaging method, when combined with MRI, can better guide prostate biopsies to find high-grade (more serious) prostate cancer. You might be able to join if you are a man between 18 and 90 years old and have a suspicious area on a recent MRI scan of your prostate. The study aims to enroll 30 participants, but its current status is unclear.

Study design
This is an interventional study, meaning participants will receive specific procedures. It plans to enroll 30 men.
What's involved
You would receive flotufolastat F 18 intravenously (into a vein) and then have a PET/CT scan. Within six months, you would undergo two types of prostate biopsies in a random order.
Compensation
Not stated in the trial record.
Follow-up
The primary goal is to detect high-grade cancer at the time of biopsy.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07164027

Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial

Recruiting
EARLY_PHASE1Ages 18–90InterventionalDiagnostic
Jonsson Comprehensive Cancer Center
~30 participants
Updated 2026-03-10 on ClinicalTrials.gov
What's tested:Biopsy of ProstateBiospecimen CollectionComputed TomographyFlotufolastat F-18 GalliumPositron Emission Tomography

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Detection of high-grade cancer (grade group [GG] ≥ 2)
Measured over At time of biopsy

Conditions

Prostate Carcinoma

Explore related trials

Prostate Carcinoma

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Wayne Brisbane · PRINCIPAL_INVESTIGATOR · UCLA / Jonsson Comprehensive Cancer Center

Who to contact

Kyla Grunden
[email protected]
310-206-7576
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Men aged 18-90 at study enrollment
Have at least one PI-RADS 3-5 lesion on MRI within the 12 months prior to enrollment

Exclusion

Contraindication to flotufolastat F 18 PET CT
Contraindication to ultrasound-guided prostate biopsy
Previous treatment of prostate cancer
Unable to discontinue blood thinners for 7 days prior to biopsy
Any investigational agents within 42 days prior to the day of the first dose
Not able to understand and to follow study instructions and requirements. This also includes the inability to complete the study imaging and or biopsy procedures due to any reason (e.g., severe claustrophobia, inability to lie still for the entire imaging time, any condition that precludes raised arms position)

What this trial measures

  • Detection of high-grade cancer (grade group [GG] ≥ 2)At time of biopsy

    Results of prostate specific membrane antigen (PSMA)- and magnetic resonance imaging (MRI)-guided biopsy will be compared to the results of systematic biopsy in the same patient.